Fig. 2: Survival analysis and circulating viral burden of AGMs challenged with LASV Togo and treated with 4′-FIU.
From: Oral 4′-fluorouridine rescues nonhuman primates from advanced Lassa fever
a, Kaplan–Meier survival curves of AGMs (n = 5) challenged with LASV and treated with 4′-FIU beginning at 6 DPI. Survival data from positive control AGMs from the pilot study (PC, n = 5) and one untreated in-study control are included for comparison. Statistical significance between treated and untreated animals was determined using the Mantel–Cox log-rank test (P = 0.002, two-tailed). b, Viral load as measured by RT–qPCR amplification of LASV vRNA in whole blood sampled at the indicated time points. Data from positive control AGMs from the pilot study are included for comparison. c, Plaque titration of circulating infectious virus from plasma sampled at the indicated time points. Data from positive control AGMs from the pilot study are included for comparison. d, Viral load in tissues from AGMs as assessed by RT–qPCR. vRNA copy numbers were assessed by RT–qPCR from tissues collected at necropsy. Data from positive control AGMs from the pilot study are included for comparison. The asterisk next to ‘Lung’ indicates that data shown for the AGM controls from the pilot study represent the mean titre of six individual sections of lung assayed in Fig. 1d. In b–d, data for individual monkeys and time points were derived from the mean of two replicate assays. Data for the AGM pilot study control cohort are shown as the geometric mean titre ± geometric s.d. The horizontal dotted line indicates the LLOQ for each assay (1,000 GE ml−1 or 1,000 GE per g tissue for RT–qPCR, 25 PFU ml−1 for plaque titration).
